Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.01%||170.19||0.7%||$968.89m|
|MRK||Merck & Co., Inc.||1.18%||89.53||0.7%||$782.75m|
|LLY||Eli Lilly & Co.||0.15%||302.94||1.1%||$765.74m|
|BMY||Bristol-Myers Squibb Co.||1.59%||74.97||1.0%||$667.48m|
|SIGA||SIGA Technologies, Inc.||2.70%||22.79||0.0%||$421.60m|
|ALNY||Alnylam Pharmaceuticals, Inc.||-3.19%||223.37||8.1%||$270.23m|
|GBT||Global Blood Therapeutics, Inc.||-0.02%||66.59||5.6%||$260.89m|
|HZNP||Horizon Therapeutics Plc||-3.63%||67.12||5.4%||$204.87m|
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.